Zelira in the news
Stockhead – Dr Boreham’s Crucible: Zelira’s share price could wake up once sales of its pot-based insomnia drug start
Zelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a self-serving myth perpetuated by overzealous users of the intoxicating herb: no one has ever been recorded as overdosing on cannabis over millennia of usage.
“The safety profile is amazing and that’s the bit that everyone has forgotten,” Dr Hopkins says.